These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30097845)

  • 1. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M
    Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
    Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
    J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
    Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
    Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Beck KR; Kim N; Khalili M
    Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
    Aluzaite K; Fraser M; Johnson S; Giles H; Schultz M
    N Z Med J; 2020 Nov; 133(1525):53-61. PubMed ID: 33223548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Nagaty A; Helmy SH; Abd El-Wahab EW
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    El Kassas M; Abdeen N; Omran D; Alboraie M; Salaheldin M; Eltabbakh M; Farghaly R; Emadeldeen M; Afify S; Sweedy A; Ghalwash A; Abbass A; Ezzat S; Tahoon M; ELshazly HM; Hamdy H; Omar H
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e877-e882. PubMed ID: 34560693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
    Charatcharoenwitthaya P; Wongpaitoon V; Komolmit P; Sukeepaisarnjaroen W; Tangkijvanich P; Piratvisuth T; Sanpajit T; Sutthivana C; Bunchorntavakul C; Sobhonslidsuk A; Chonprasertsuk S; Siripipattanamongkol C; Sethasine S; Tanwandee T;
    BMC Gastroenterol; 2020 Mar; 20(1):47. PubMed ID: 32138687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
    Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.